Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04014374 · ClinicalTrials.gov registry record
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
A clinical trial of Cutaneous T Cell Lymphoma and Leukemia/Lymphoma, sponsored by Kyowa Kirin.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04014374 is a study of Cutaneous T Cell Lymphoma and Leukemia/Lymphoma that is actively recruiting participants, run by Kyowa Kirin. The registered enrollment target is 150 participants, above the 61-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (146% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04014374, a study of Cutaneous T Cell Lymphoma and Leukemia/Lymphoma, is actively recruiting participants, sponsored by Kyowa Kirin.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
Conditions Studied
Study Locations (1)
Wisconsin
- CIBMTR - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-09-10 |
| Est. Completion | 2030-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04014374
The ClinicalTrials.gov registry entry for NCT04014374 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 61-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (146% higher). The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT04014374 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04014374 about?
NCT04014374 is a clinical study titled "Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab". This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
What is the current status of trial NCT04014374?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2019-09-10. Estimated completion is 2030-02.
What conditions does trial NCT04014374 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma, Leukemia/Lymphoma, ATLL.
Who is sponsoring clinical trial NCT04014374?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04014374 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
RECRUITING
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.